SVRA May 2024 2.500 call
| Previous Close | 2.1000 |
| Open | 2.3500 |
| Bid | 0.1000 |
| Ask | 4.8000 |
| Strike | 2.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 2.3500 - 2.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 175 |
Business WireSavara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa., May 19, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara’s partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP.
Business WireSavara Announces New Employment Inducement Grant
AUSTIN, Texas, May 16, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
Business WireSavara Reports First Quarter 2024 Financial Results and Provides Business Update
LANGHORNE, Pa., May 09, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update.
